Bisphosphonate-associated orbital inflammation-a case report and review

Orbit

Volumn 31, Issue 2, 2012, Pages 119-123

  Peterson, Jared D ^a   Bedrossian, Edward H ^a  

^a WILLS EYE HOSPITAL   (United States)

Author keywords

Adverse drug effect; Bisphosphonate; Corticosteroids; Orbital inflammation

Indexed keywords

ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPLEGIC AGENT; METHYLPREDNISOLONE; STEROID; ZOLEDRONIC ACID;

ADULT; ANTERIOR EYE CHAMBER; BISPHOSPHONATE ASSOCIATED ORBITAL INFLAMMATION; CASE REPORT; CHEMOSIS; CONJUNCTIVAL HYPEREMIA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; EXOPHTHALMOS; EXTRAOCULAR MUSCLE; EYE PAIN; FEMALE; HEADACHE; HUMAN; ORBIT INFLAMMATION; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; STEROID THERAPY;

EID: 84859603015     PISSN: 01676830     EISSN: 17445108     Source Type: Journal    
DOI: 10.3109/01676830.2011.648818     Document Type: Review

References (18)

1. US Public Health Services. Department of Health and Human Services. Bone health and osteoporosis: A report of the Surgeon General. www.surgeongeneral. gov/library/bonehealth/docs/Chapter-4.pdf. Accessed on 6 June 2011.
2. Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 2011;71:791-814.
3. Caraglia M, Santini D, Marra M, et al. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006;13:7-26.
4. Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-392. (Pubitemid 30463353)
5. Kunzmann V, Bauer E, Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 1999;340:737-738.
6. Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003;135:219-222. (Pubitemid 36151800)
7. Mbekeani JN, Slamovits TL, Schwartz BH, et al. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 1999;117:837-838. (Pubitemid 29265053)
8. Ryan PJ, Sampath R. Idiopathic orbital inflammation following intravenous pamidronate. Rheumatology (Oxford) 2001;40:956-957. (Pubitemid 32816080)
9. Subramanian PS, Kerrison JB, Calvert PC, et al. Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer. Arch Ophthalmol 2003;121:1335-1336. (Pubitemid 37128418)
10. Benderson D, Karakunnel J, Kathuria S, et al. Scleritis complicating zoledronic acid infusion. Clin Lymphoma Myeloma 2006;7:145-147. (Pubitemid 44596598)
11. Phillips PM, Newman SA. Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma. Arch Ophthalmol 2008;126:137-139.
12. Sharma NS, Ooi JL, Masselos K, et al. Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med 2008;359:1410-1411.
13. Procianoy F, Procianoy E. Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis. Osteoporos Int 2010;21:1057-1058.
14. Seth A, Anderson DP, Albiani DA, et al. Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer. Can J Ophthalmol 2009;44:467-468.
15. Yang EB, Birkholz ES, Lee AG. Another case of bisphosphonate- induced orbital inflammation. J Neuroophthalmol 2010;30:94-95.
16. Missotten G, Verheezen Y. Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma. Bull Soc Belge Ophtalmol 2010;315:23-24.
17. Yeo J, Jafer AK. Zolendronate associated inflammatory orbital disease. N Z Med J 2010;123:50-52.
18. Black DM, Delmas PD, Eastell R, et al.; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822. (Pubitemid 46698462)